Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, Bevacizumab, HAIC, and SBRT in Locally Advanced HCC
NCT07012798Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Sep 2025; status: recruiting.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07012798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012798.